Clinical value meets financial sustainability
A Technology That Pays for Itself
For primary care practices evaluating autonomous AI retinal screening, the financial question is straightforward: does the reimbursement support sustainable deployment? The answer, increasingly, is yes.
Reimbursement Under CPT 92229
CPT code 92229 — established specifically for autonomous AI retinal imaging — provides reimbursement for the screening procedure when performed using an FDA-cleared autonomous system. Medicare rates and major commercial payer coverage make this a billable service that generates revenue per patient screened.
For a practice screening 10 to 15 eligible patients per day, the economics are compelling. Equipment costs are typically recovered within months, and the service becomes a sustainable addition to the diabetes care workflow.
Operational Efficiency
Unlike specialist-dependent models, autonomous AI screening does not require a physician or trained technician to interpret results. Medical assistants can perform the imaging procedure after brief training, freeing clinician time while expanding the services offered to patients.
The screening process takes less than five minutes, integrates naturally into a diabetes management visit, and generates documentation that supports quality reporting and value-based care metrics.
Quality Metrics and Value-Based Care
Retinal screening rates are tracked quality metrics in major value-based care programs, including HEDIS measures and CMS quality reporting initiatives. Practices that systematically screen their diabetic population with autonomous AI can demonstrate improved performance on these measures — directly impacting quality bonuses and shared savings calculations.
The Cost of Not Screening
There is also a downstream cost argument. Patients with undetected advanced retinopathy require more expensive interventional treatments — laser therapy, anti-VEGF injections, vitreoretinal surgery. Health economic modeling of EyeArt deployment shows cost savings of over $300 per patient over a five-year horizon, driven primarily by earlier detection and reduced downstream treatment costs.